Comparing the current results to its competitors, Cellectar Biosciences Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.8 %, recorded in the same quarter.
Cellectar Biosciences Inc , slower than the average decrease reported by the company's competitors of -27.15 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -27.15 %
September 3, 2025
: Cellectar Biosciences is making notable strides in the treatment of pancreatic cancer with its promising novel drug CLR 121225, showcased at the American Association for Cancer Research (AACR) Special Conference. This article discusses the implications of the presented data and how it contributes to the ongoing fight against one of the most aggressive forms of cancer.Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), remains one of the most challenging cancers to treat due to its typically late diagnosis and hypoxic tumor microenvironment. The American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research serves as a pivotal platform for enlightening ...
December 10, 2024
Cellectar Biosciences, a prominent player in the pharmaceutical research and development sector, recently provided a strategic update highlighting significant progress within its clinical pipeline, current market performance, and corporate restructuring efforts. At the heart of the company s strategic focus is iopofosine I 131, a promising late-stage clinical program that has showcased compelling data from Phase 2 clinical trials, indicating considerable promise for future market penetration and success.The development of iopofosine I 131 represents a vital component of Cellectar s growth strategy, as it addresses a substantial market opportunity in the field of targeted cancer therapies. The promising resul...
November 21, 2024
: The pharmaceutical landscape continuously evolves through collaborations and technological advancements. A recent partnership between NorthStar Medical Radioisotopes and Cellectar Biosciences highlights the potential of Actinium-225 (Ac-225) in advancing therapeutic radioisotope applications. This article analyzes the implications of this agreement and contextualizes it within the ongoing market performance challenges faced by Cellectar.The utilization of radioisotopes in medical treatments has gained traction, particularly in the field of oncology, where targeted therapies can increase the precision of treatment while minimizing damage to healthy tissue. An essential development in this area is the strate...
January 30, 2024
Cellectar Biosciences has begun enlisting participants for its Phase 1b clinical study focusing on pediatric high-grade gliomas, a significant milestone in oncological research. The U.S. clinical-stage biopharmaceuticals company, notable for pursuing novel therapeutic solutions in cancer, announced that the first patient enrollment has occurred. The research involves the utilization of the company’s experimental drug, Iopofosine I 131.The team at Cellectar Biosciences is embarking on the study with monetary support reaching the value of $2 million, extended by the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH). The NCI grant underscores the significance of the resear...
January 8, 2024
Promising Results: Cellectar Biosciences Iopofosine I 131 Demonstrates Success as a Groundbreaking Radiotherapy Candidate for Waldenstroms MacroglobulinemiaIn a groundbreaking development, Cellectar Biosciences, a leading clinical biopharmaceutical company dedicated to combatting cancer, has announced positive topline data from its pivotal clinical study, CLOVER WaM. The study focused on evaluating the efficacy of iopofosine I 131 as a potential first-in-class targeted radiotherapy candidate for patients suffering from relapsed or refractory Waldenstroms macroglobulinemia (WM). Specifically, the trial investigated patients who had previously received at least two lines of therapy, including Bruton tyrosine ...
In a bold stride toward combating pediatric cancer, Cellectar Biosciences have revealed their plans to expand the collaboration with the Wisconsin Alumni Research Foundation (WARF) in an exclusive licensing agreement meant to develop and commercialize pediatric cancer treatments. This leap signifies a potential breakthrough in the fight against one of the leading causes of death in children. Initiated by Cellectar, a clinical-stage biopharmaceutical company focused on developing drugs for the management and treatment of cancer, and WARF, a globally recognized leader in university-based technology transfer, this partnership intends to leverage their combined expertise in medical research and drug de...
Publicly Traded Peers of Cellectar Biosciences Inc
Hookipa Pharma inc Share Performance
+0.88%
This Quarter
Hookipa Pharma inc
Profile
Hookipa Pharma Inc. is a biotechnology company that focuses on developing immunotherapeutics targeting infectious diseases and various forms of cancer. Their business model revolves around leveraging their proprietary technology platform, known as VaxWave, to design and manufacture a new class of immunotherapies. By collaborating with strategic partners and conducting clinical trials, Hookipa aims to bring these innovative treatments to market to improve patient outcomes and address unmet medical needs.
Arbutus Biopharma Corp is a biopharmaceutical company focused on discovering and developing innovative therapies for patients suffering from Hepatitis B. They aim to utilize their proprietary technologies to both advance their internal pipeline and collaborate with partners to develop a cure for Hepatitis B. Their business model revolves around leveraging their expertise and strategic partnerships to create effective treatments that address the unmet needs of Hepatitis B patients.
Abeona Therapeutics Inc is a biopharmaceutical company focused on developing gene and cell therapies for rare genetic diseases. Their business model revolves around identifying and acquiring promising technologies, conducting pre-clinical and clinical research, and eventually bringing these therapies to the market. They collaborate with academic institutions, medical centers, and patient advocacy groups to advance their pipeline and provide solutions for currently untreatable genetic disorders.
Sellas Life Sciences Group Inc is a biopharmaceutical company that focuses on developing and commercializing immunotherapeutic products for various cancer indications, utilizing innovative technologies. The company aims to meet the need for more effective treatment options by leveraging its expertise in immuno-oncology and precision medicine.
Sources:
Cellectar Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cellectar Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
